Pneumococcal pneumonia: Update on therapy in the era of antibiotic resistance

Bernard Karnath, Akua Agyeman, Albert Lai

Research output: Contribution to journalReview articlepeer-review


The emergence of drug-resistant pneumococci has changed the empiric treatment of community-acquired pneumonia. Newer fluoroquinolones with activity against Streptococcus pneumoniae offer an alternative in the treatment of infection with penicillin-resistant strains. These agents are not recommended as first-fine therapy because of concerns about the development of resistance. Reserve the fluoroquinolones for patients who are allergic to macrorides and β-lactams, have failed to respond to a first-line agent, or have a documented infection with a highly resistant strain. The pneumococcal vaccine is recommended for all persons aged 65 years and older, adults with chronic cardiopulmonary diseases, and immunocompromised persons. Consider revaccination every 6 years in asplenic patients and immunocompromised persons. In addition, vaccination against influenza can help prevent secondary pneumonia and reduce the need for hospitalization.

Original languageEnglish (US)
Pages (from-to)321-326
Number of pages6
Issue number3
StatePublished - Mar 2003

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Pneumococcal pneumonia: Update on therapy in the era of antibiotic resistance'. Together they form a unique fingerprint.

Cite this